Standard usage and usual dosage of neratinib/neratinib

Neratinib is an irreversible tyrosine kinase inhibitor that mainly targets HER2 (human epidermal growth factor receptor 2) and is widely used in patients with HER2-positive breast cancer, especially as extended adjuvant therapy after early treatment or for advanced or metastatic breast cancer. The standard recommended dose is 240 mg orally, or 6 tablets, taken daily to increase bioavailability and reduce gastrointestinal discomfort.

In early-stage breast cancer, treatment cycles can last up to 12 months and are designed to reduce the risk of recurrence. For advanced or metastatic breast cancer, neratinib is usually given in combination with capecitabine in a 21-day cycle, with neratinib given for 21 consecutive days, with capecitabine added on days 1 to 14, until disease progression or unacceptable toxicity occurs.

In order to improve patient tolerance, some clinical practices will adopt a "dose escalation" strategy starting with a lower dose and then gradually increasing it to the recommended dose. It is often used for patients at risk of severe diarrhea. At the same time, if the patient experiences serious adverse reactions, such as grade 3 or above diarrhea, elevated liver enzymes, or other toxic reactions, treatment must be interrupted and the dose adjusted according to the specific situation. For patients with severe liver damage, it is recommended to reduce the starting dose to 80 mg to reduce the risk of drug accumulation in the body and improve safety.

It should be noted that neratinib is an oral drug for long-term use. Patients must strictly follow the doctor's instructions and are not allowed to increase or decrease the dose or stop the drug on their own to ensure the therapeutic effect and reduce the incidence of side effects. Doctors often also combine anti-diarrheal drugs such as loperamide to control common diarrhea during initial treatment, thereby helping patients successfully complete the course of treatment.

Reference materials:https://en.wikipedia.org/wiki/Neratinib